Histological improvement (dichotomous) · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes histological improvement at 6 weeks (dichotomous) compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Clinical remission · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with ileal pouch‐anal anastomosis
Allopurinol showed no clear difference in no episodes of acute pouchitis compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
1 finding from 1 review
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in incidence of oesophageal squamous cell carcinoma ‐ modified ITT… compared with control (moderate certainty).
1 finding from 1 review
Overall survival ‐ FOLFIRINOX · advanced pancreatic cancer
Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).
1 finding from 1 review
Overall survival (1‐year · people with pancreatic and periampullary adenocarcinoma
It is very uncertain whether extended changes overall survival (1‐year compared with standard lymph node resection (very low certainty).
1 finding from 1 review